Dialyser surface area: is it based on weight or height?

For maintenance haemodialysis in adults, major guidelines do not recommend a fixed formula that directly assigns a dialyser membrane surface area—such as 1.4, 1.6, 1.8, or 2.1 m²—according to body weight, height, or body surface area (BSA).

This distinction matters because some dialysis units use local tables such as:

• Below 60 kg → 1.4 m² dialyser

• 60–80 kg → 1.6 m²

• Above 80 kg → 1.8–2.1 m²

Such tables may be useful local starting protocols or reflect manufacturers’ recommendations, but they are not a formal KDIGO or KDOQI standard.

1. What does KDOQI say?

The KDOQI haemodialysis adequacy guideline focuses on the dialysis dose actually delivered to the patient, not on dialyser surface area per kilogram of body weight.

For conventional three-times-weekly haemodialysis in patients with little residual kidney function, the commonly cited target is:

Target spKt/V ≈ 1.4 per session

with a minimum delivered dose of:

Delivered spKt/V ≥ 1.2

The underlying relationship is:

Larger patient → larger urea distribution volume V → greater clearance requirement

This may require an increase in:

K, dialysis time t, or both

A larger dialyser surface area can be one way to increase effective clearance K, but it is not the only way.

The guidelines do not provide an equation of the form:

Dialyser surface area = X × patient weight

2. Why are larger dialysers often used for larger patients?

The reason relates to the concept of:

Kt/V

where:

K = effective urea clearance
t = dialysis treatment time
V = urea distribution volume, which broadly relates to total body water

A larger patient generally has a larger V.

To achieve the same Kt/V, the prescription may therefore require:

Higher K and/or longer treatment time

A dialyser with:

• a larger effective surface area, and/or

• a higher KoA

may increase K, provided that blood flow (Qb), dialysate flow (Qd), access performance, and treatment time are adequate.

The relationship is therefore:

Patient size → required clearance → dialyser selection

not simply:

A particular weight → one fixed dialyser area

3. What about height?

Height is also relevant, but indirectly. Height and weight influence:

• Total body water.

• Body surface area.

• Urea distribution volume V.

• Metabolic mass.

KDOQI has discussed BSA-normalized dialysis dosing because normalizing only to urea distribution volume can produce an imperfect estimate in some people, particularly smaller patients and some women.

That discussion concerns how dialysis dose is normalized; it is not a rule for selecting dialyser membrane area.

4. A patient’s BSA is not the same as dialyser surface area

Both values are expressed in square metres, but they describe different things. BSA is an estimate of patient size; dialyser surface area is a device property that contributes to mass transfer together with membrane characteristics and flow conditions.

5. What about common weight tables?

Some centres use approximate tables such as:

These can be used as an approximate practical starting point, but they are not a formal KDIGO, KDOQI, or ERA standard.

They are often based on:

• Local protocols.

• Manufacturer recommendations.

• Traditional clinical practice.

• The dialyser’s expected clearance and KoA.

They should not be presented as a guideline-mandated rule.

6. What about children?

The situation is distinctly different in children. There is a much closer relationship between:

The child’s body surface area

and:

Dialyser surface area

A practical paediatric approach is to select a dialyser area near the child’s BSA and avoid a disproportionately large device.

Some contemporary recommendations for paediatric HDF use approximately:

Dialyser surface area ≈ patient BSA

and generally prefer that the dialyser should not greatly exceed:

About 120% of BSA

For example, if:

BSA = 0.8 m²

a dialyser in the range of:

0.8–1.0 m²

may be selected rather than an adult 1.8- or 2.0-m² dialyser.

This matters in children because of:

• Extracorporeal blood volume.

• Priming volume.

• Risk of hypotension.

• Limited achievable Qb.

7. What about HDF?

In haemodiafiltration, patient size also matters, but in a different way.

Recent ERA/EuDial statements emphasize interpreting convection volume in relation to the patient’s size and treatment context.

The ability to achieve a high convection volume also depends on:

• Qb.

• Treatment time.

• Filtration fraction.

• Vascular access.

• Dialyser properties.

It is not determined by dialyser surface area alone.

How is a dialyser selected in adults?

A modern, biocompatible high-flux dialyser may be used as a starting point. Depending on the available product and the patient, an initial surface area often lies in the range of 1.4–1.8 m², but this is not a universal prescription.

The team then considers:

The patient

Body size and total body water
↓
Residual kidney function
↓
Metabolic state

The dialysis prescription

Qb
↓
Qd
↓
Treatment time
↓
Number of sessions

Dialyser properties

Surface area
↓
KoA
↓
Beta-2-microglobulin clearance
↓
KUF
↓
Membrane type

Finally, the team measures the dose actually delivered:

Delivered spKt/V and/or URR

together with volume control, symptoms, blood pressure, biochemical results, and treatment tolerance.

If clearance is inadequate, the response should not automatically be a larger dialyser. A structured review includes:

Vascular access and recirculation → Qb → treatment time → KoA and surface area → Qd

Summary

The most important practical rule

Do not select dialyser surface area directly from body weight.

Instead, think through the chain:

Patient size → urea distribution volume V → required dialysis dose → required K → Qb + time + KoA/surface area

Values such as 1.4, 1.6, 1.8, or 2.1 m² are not doses tied to fixed body weights. They are different device options used, with the rest of the prescription, to achieve the clearance required for an individual patient.